Envista Holdings Corporation NVST is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case.
The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for execution setbacks even as operating momentum improves.
NVST’s Earnings Recovery Supports the Bull Case
Adjusted earnings were 41 cents per share in the second quarter of 2026, up 57.7% year over year. Operating profit rose 73.4% to $80.3 million, while the operating margin expanded 420 basis points to 11%.
The Zacks Consensus Estimate calls for 2026 earnings of $1.53 per share, up from $1.19 in 2025. Management also raised adjusted earnings guidance to $1.50-$1.55 and adjusted EBITDA growth guidance to 11%-14%, reinforcing expectations for a meaningful profit recovery.
Image Source: Zacks Investment Research
Envista’s Valuation Leaves Less Room for Error
NVST trades at 18.0X forward 12-month earnings, above its five-year median of 17.5X and the Zacks sub-industry’s 16.2X. That premium suggests investors are already assigning value to the improving earnings trajectory.
The picture is not uniformly expensive. NVST’s multiple remains below the Zacks Medical sector’s 20.5X and the S&P 500’s 20.7X. Still, with the stock above its own historical median, further upside may depend more heavily on sustained execution.
Image Source: Zacks Investment Research
NVST’s Growth Drivers Extend Beyond One Quarter
Second-quarter core sales increased 5%. Equipment & Consumables core sales rose 8.5%, supported by high-single-digit growth in consumables and diagnostics, while Spark grew at a double-digit rate and implants advanced at a low-single-digit pace.
New products and the Versah acquisition add more growth avenues. Align Technology, Inc. ALGN reported an 8.2% year-over-year increase in second-quarter 2026 clear aligner revenues, showing continued activity in a category where Spark competes. DENTSPLY SIRONA Inc. XRAY, another diversified dental-products company, reported $898 million in second-quarter 2026 net sales and reiterated its 2026 outlook.
Envista’s Risks Could Limit Further Re-Rating
China pricing remains a major uncertainty. Management expects the orthodontic volume-based procurement program to produce a large price reduction, while the second implant program could reduce prices by about 10%-15%.
Tariff costs increased about $5 million year over year in the second quarter and are expected to remain at similar quarterly levels in the second half. Brackets and wires also declined at a high-single-digit rate, highlighting uneven performance across the portfolio.
NVST’s Style Profile Favors Value and Momentum
The investment case has improved, but the above-median valuation raises the bar for continued earnings delivery. Investors weighing the stock now have stronger operating trends on one side and policy, tariff and product-execution risks on the other.
NVST currently carries a Zacks Rank #1 (Strong Buy). It also has a Value Score of B, Momentum Score of B and VGM Score of B, all favorable readings when paired with a top Zacks Rank. Its Growth Score of D is the main counterweight, reflecting a less favorable growth profile despite the current earnings rebound.
You can see the complete list of today's Zacks #1 Rank stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).